Recently, Shanghai LKtime Biotechnologies Co., Ltd. (referred to as "LKtime Biotech") and Zhejiang Boxiao Biopharmaceutical Co., Ltd. (referred to as "LKtime Biotech") officially signed a strategic cooperation agreement. This collaboration covers multiple critical areas, including biopharmaceutical process development, clinical sample production, BLA (Biologics License Application) submission, and commercial production. It marks a comprehensive partnership between the two innovative companies in various fields, particularly in the development and production of XDC (X-drug conjugate) drugs, jointly opening a new chapter of innovative development.

Yan Wei, General Manager of Boxiao Biopharmaceutical, expressed high expectations for this collaboration: "Reaching this strategic partnership with LKtime Biotech marks a critical step for Boxiao Biopharmaceutical in our transformation into an innovative biopharmaceutical company with a full industry chain. This is not only a significant milestone in our expansion from small molecules to the biologics field but also a reflection of the industry's multi-dimensional innovation development encompassing 'small molecules + biologics + XDC'.

By integrating Boxiao Biopharmaceutical's strengths in small molecule drug design, targeted delivery system development, and clinical translation with LKtime Biotech's exceptional capabilities in biologics process development and large-scale production, we will jointly establish a comprehensive XDC (X-drug conjugate) drug development platform spanning from proof-of-concept to commercial production. This platform will significantly enhance the efficiency and quality of novel XDC drug development, potentially delivering breakthrough therapies in critical disease areas such as oncology and autoimmune diseases. It will also accelerate Boxiao Biopharmaceutical's innovation and development progress in the XDC drug field."

Yan Wei further emphasized, "In addition to our in-depth collaboration in the XDC field, we will also explore cooperative opportunities with LKtime Biotech in cutting-edge areas such as synthetic biology. This field holds significant importance in various biopharmaceutical domains, including new drug development, drug production, vaccine development, and delivery systems. Leveraging the profound technological expertise and talent from both sides, we are confident in setting new industry benchmarks in these frontier areas."

Mr. Zhang Lei, Founder and CEO of LKtime Biotech, expressed strong confidence in this collaboration: "We are extremely pleased to establish this milestone strategic partnership with Boxiao Biopharmaceutical. As a biologics CDMO company that has recently completed its Series B financing, earning the trust of Boxiao Biopharmaceutical not only represents high recognition of our service capabilities but also serves as a powerful testament to the sustainability of the development model for the entire biopharmaceutical industry chain. We will provide Boxiao Biopharmaceutical with high-level, high-quality technical support and commercial production services.

In addition, we will fully leverage LKtime Biotech' leading expertise in biologics process development, large-scale production, and quality control, combined with Boxiao Biopharmaceutical's outstanding capabilities in innovative small-molecule drug design and development, to jointly build an industry-leading one-stop XDC drug R&D and production platform. This platform will integrate end-to-end capabilities, from target discovery, molecular design, bioconjugation, and process development to large-scale production. It will significantly shorten the R&D cycle for XDC drugs while improving project success rates and effectively reducing R&D costs without compromising quality. Through this deep collaboration, we will not only provide strong support for Boxiao Biopharmaceutical in the development and industrialization of XDC drugs but also drive the entire industry toward a more efficient and precise drug R&D model, ultimately benefiting patients worldwide."